- Record: found
- Abstract: found
- Article: not found
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
A D Norden
1 ,
G S Young ,
K Setayesh ,
A Muzikansky ,
R Klufas ,
G L Ross ,
A S Ciampa ,
L G Ebbeling ,
B Levy ,
J Drappatz ,
S Kesari ,
P Y Wen
Mar 04 2008
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor, may have activity in recurrent malignant gliomas. At recurrence some patients appear to develop nonenhancing infiltrating disease rather than enhancing tumor.